Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts

Biochemical Pharmacology

Volumn 51, Issue 5, 1996, Pages 629-634

  De Pooter, Christel M ^a   Van Oosterom, Allan T ^a   Scalliet, Pierre G ^b   Maes, Robert A ^c   De Bruijn, Ernst A ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Hôpital Saint Luc   (Belgium)

^c NONE

Author keywords

cisplatin; cisplatin resistance; DNA adducts; human cell lines; ovarian cancer

Indexed keywords

CISPLATIN;

ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA REPAIR; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IONIZING RADIATION; OVARY CANCER; PREDICTION; PRIORITY JOURNAL;

EID: 0029935541     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(95)02229-5     Document Type: Article

References (39)

1. Osmark M and Perovic S, Multiple fractions of gamma rays induced resistance to cis-dichloro-diammineplatinum (II) and methotrexate in human HELA cells. Int J Radiat Oncol Biol Phys 16: 1537-1541, 1989.
2. Hill BT, Shellard SA, Hosking LK, Fichtinger-Schepman AMJ and Bedford P, Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-dichloro-diammineplatinum(II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int J Radiat Oncol Biol Phys 19: 75-83, 1990.
3. De Pooter ChMJ, Scalliet PG, Elst H, Huybrechts JJ, Gheuens EEO, Van Oosterom AT, Fichtinger-Schepman AMJ and de Bruijn EA, Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation. Cancer Res 51: 4523-4527, 1991.
4. Dempke WCM, Shellard SA, Hosking LK, Fichtinger-Schepman AMJ and Hill BT, Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro. Carcinogenesis 13: 1309-1215, 1992.
5. Kuppen PJ, Schuitemaker H, Van't Veer LJ, De Bruijn EA, Van Oosterom AT and Schrier PI, cis-Diamminedichloroplatinum (II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 48: 3355-3359, 1988.
6. Saburi Y, Nakagawa M, Ono M, Sakai M, Muramatsu M, Kohno K and Kuwano M, Increased expression of glutathione S-transferase gene in cis-Diamminedichloroplatinum(II)-resistant variants of a Chinese hamster cell line. Cancer Res 49: 7020-7025, 1989.
7. Twentyman PR, Wright KA and Rhodes T, Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin. Int J Radiat Oncol Biol Phys 20: 217-220, 1991.
8. Kelland LR, Mistry P, Abel G, Loh SY, O'Niel CF, Murrer BA and Harrap KR, Mechanism-related circumvention of acquired cis-Diamminedichloroplatinum(II)-resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV)dicarboxylates. Cancer Res 52: 3857-3864, 1992.
9. Christen RD, Jekunen AP, Jones JA, Thiebau F, Shalinsky DR and Howell SB. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alterations of microtubules. J Clin Invest 92: 431-440, 1993.
10. Eicholtz-Wirtz H, Reidl G and Heitel B, Radiation-induced transient cisplatin resistance in murine fibrosarcoma cells associated with elevated metallothionein content. Br J Cancer 67: 1001-1006, 1993.
11. Eicholtz-Wirtz H and Heitel B, Cisplatin resistance in mouse fibrosarcoma cells after low-dose irradiation in vitro and in vivo. Br J Cancer 70: 579-584, 1994.
12. Zhen W, Link J, O'Connor P, Reed E, Parker R, Howell SB and Bohr VA, Increased gene-specific repair of cis-platin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689-3698, 1992.
13. De Bruijn E, Kuppen P, Leeflang P, Slee P and Van Oosterom A, Construction in vitro area under the curves for testing of antitumor agents with the mean residence time as starting-point. Br J Pharmacol 89: 510, 1986.
14. Fichtinger-Schepman AMJ, Van Der Veer JL, Den Hartog JHL, Lohman PHM and Reedijk J, Adducts of the antitumor drug cis-diamminedichloroplatinurn(II) with DNA: Formation, identification and quantitation. Biochemistry 24: 707-713, 1985.
15. Fichtinger-Schepman AMJ, Baan RA, Luiten-Schuite A, Van Dijk M and Lohman PHM, Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum(II) and analysis of adduct-related DNA-unwinding. Chem-Biol Interact 55: 275-288, 1985.
16. Fichtinger-Schepman AMJ, Van Oosterom AT, Lohman PHM and Berends F, Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 47: 3000-3004, 1987.
17. de Bruijn EA, Chromatographic analysis of anticancer drugs. In: Monitoring anticancer agents (Ed. EA de Bruijn), pp. 23-119. Pasmans, The Hague, 1992.
18. Sklar MD, Increased resistance to cis-Diamminedichloroplatinum(II) in NIH3T3 cells transformed by ras oncogenes. Cancer Res 48: 793-797, 1988.
19. Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M and Saijo N. Resistance to anti-cancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 63: 237-241, 1991.
20. Peters GJ, Wets M, Keepers YPAM, Oskam R, Van Ark J, Noordhuis P, Smid K and Pinedo HM, Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 54: 450-455, 1993.
21. Dirix LY, Gheuens EEO, Van Der Heyden S, Van Oosterom AT and de Bruijn EA, Cytotoxic activity of 7-N-(2-((2-(γ-L-glutamyl-amino)-ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns. Anti-Cancer Drugs 5: 343-354, 1994.
22. Andrews PA and Howell SB, Cellular pharmacology of cisplatin: Perspectives on mechanisms of required resistance. Cancer Cells 2: 35-43, 1990.
23. Gately DP and Howell SB, Cellular accumulation of the anti-cancer agent cisplatin: A review. Br J Cancer 67: 1171-1176, 1993.
24. Verdrik CPJ, Bergers JJ, De Jong WH and Steerenberg PA, Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 29: 413-429, 1992.
25. Bungo M, Fujiwara Y, Kasahare K, Nahagawa K, Oke Y, Sasaki Y, Irino S and Saijno N, Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: Relation to DNA damage and repair. Cancer Res 50: 2549-2553, 1990.
26. Eastman A, Schultz N, Sheibani N and Sorenson CM, Mechanisms of resistance to platinum drugs. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Nicolini M (Ed.) pp. 178-196, Martinus Nijhoff, Dordrecht, 1988.
27. Richon VM, Schultz N and Eastman A, Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia. Cancer Res 47: 2056-2061, 1987.
28. Dijt FJ, Fichtinger-Schepman AMJ, Berends F and Reedijk J, Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 48: 6058-6062, 1988.
29. Bedford P, Fichtinger-Schepman AMJ, Masters JRM and Hill BR, Immunological detection of cis-platin-DNA adducts in human testicular and bladder tumour cell lines. Br J Cancer 56: 191, 1987.
30. Fichtinger-Schepman AMJ, Vendrik CPJ, Van Dijk-Knijnenburg WCM, De Jong WH, Van der Minnen ACE, Claessen AM, Van der Velde-Visser SD, De Groot G, Wubs KL, Sterrenberg, PA, Schornagel JH and Berends F, Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma. Cancer Res 49: 2862-2867, 1989.
31. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, Mc Koy WM, Young RC and Ozols RF, Characterisation of cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell lines and its use in evaluation of platinum analogues. Cancer Res 47: 414-418, 1987.
32. Reed E, Ostchega Y, Steinberg SM, Yupsa SH, Young RC, Ozols RF and Poirier MC, Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 50: 2256-2260, 1990.
33. Reed E, Ozols RF, Tarone R, Yuspa SM and Poirier MC, Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 84: 5024-5028, 1987.
34. Slee P, De Bruijn E, Leeflang P, Kuppen P, Van Den Berg L and Van Oosterom A, Variation on exposure to mitomycin C in an in vitro colony-forming assay. Br J Cancer 54: 951-955, 1986.
35. Hill BT, Shellard SB, Hosking LK, Fichtinger-Schepman AMJ and Bedford P, Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diamminedichloroplatinum(II) after in vitro exposure of a human teratoma cell line fractionated X-irradiation. Int J Radiat Oncol 19: 75-83, 1990.
36. Johnson SW, Perez RP, Goodwin AK, Yeung AT, Handel LM, Ozols RF and Hamilton TC, Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47: 689-697, 1994.
37. Hill BT, Scanlon KJ, Hansson J, Harstrick A and Pera M, Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 30A: 832-837, 1994.
38. Hill BT, Shellard SA, Fichtinger-Schepman AM, Schmoll HJ and Harstrick A, Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anticancer Drugs 5: 321-328, 1994.
39. Jekunen AP, Hom DK, Alcaraz JE, Eastman A and Howell SB, Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells. Cancer Research 54: 2680-2687, 1994.